TNONTenon Medical Inc. Common Stock

Record revenue and gross profit driven by surgical volume and system integration.

Revenue surges 127% year-over-year to $1.3 million, with gross margin expanding to 64% and new FDA clearance for Catamaran system poised to further improve profitability.

Moby summary of Tenon Medical, Inc.'s Q2 2026 earnings call

Tenon Medical Inc (TNON) reports a strong start to 2026 with record revenue and strategic investments despite challenges in operating expenses.

Moby summary of Tenon Medical, Inc.'s Q1 2026 earnings call

Tenon Medical Inc (TNON) reports a 92% increase in Q4 revenue and strategic advancements, despite ongoing challenges in balancing expenses and growth.

Moby summary of Tenon Medical, Inc.'s Q4 2025 earnings call

Steven Foster: Thank you, Shamali, and good afternoon to everyone. The increase in revenue for the year was primarily driven by growth in surgical procedures across both the Catamaran and SImmetry+ platforms in the back half of 2025, led by new physician users.

Tenon Medical Inc (TNON) reports a 32% revenue increase, driven by strategic acquisitions and product launches, despite rising expenses.

Steven Foster: Thank you, Rob, and good afternoon, everyone. The third quarter was a very exciting time for Tenon Medical, where our progress is really showing through in our financial results. Additionally, the integration of the SciVantage portfolio contributed meaningfully to our top-line growth, an early indication of what our portfolio expansion strategy can deliver.